Medicare covers a complete blood count when the test is ordered to evaluate or manage a specific medical condition, not as a routine screen. The qualifying diagnoses span a wide range of clinical situations, from anemia and infections to cancer surveillance and medication side effects. There is no single short list of covered diagnoses, though, because coverage rules are set at both the national and regional level, and the categories are broader than most beneficiaries realize.
Medical Necessity Is the Gatekeeper
Medicare’s foundational rule for laboratory tests is straightforward: the test must be medically necessary. For a CBC, that means your provider needs a documented reason to order the test. A vague desire to “check your blood” during an annual visit does not qualify. A claim submitted without a diagnosis code indicating medical necessity will be denied.1Labcorp. Medicare Medical Necessity The diagnosis your provider assigns must also be reflected in your medical record, so the paperwork has to match what actually brought you into the office or prompted the order.
This does not mean you need a confirmed disease before Medicare will pay. Symptoms count. If you walk in with unexplained fatigue, shortness of breath, easy bruising, recurrent fevers, or unintentional weight loss, those symptoms translate into ICD-10 codes that justify a CBC. The diagnosis code can represent a sign, symptom, or suspected condition. It does not have to be a final answer.
Diagnosis Categories That Commonly Qualify
The list of ICD-10 codes accepted for CBC coverage is long, sometimes running to several pages in a Medicare Administrative Contractor’s local coverage determination. Rather than memorizing codes, it helps to understand the broad clinical buckets that typically qualify. A CBC helps diagnose anemia, certain cancers, infections, acute bleeding, allergies, and immune deficiencies, and it is also used to monitor the blood-related side effects of various medications.2Journal of PeriAnesthesia Nursing. Understanding the complete blood count with differential Those categories translate into concrete qualifying scenarios:
- Anemia and blood loss: Iron deficiency, vitamin B12 or folate deficiency, chronic disease anemia, sickle cell disease, thalassemia, and any condition causing significant blood loss such as gastrointestinal bleeding or heavy menstrual periods.
- Infections: Bacterial, viral, fungal, and parasitic infections where the white blood cell count helps gauge severity or guide treatment. This includes sepsis workups, pneumonia evaluation, urinary tract infections with systemic signs, and HIV monitoring.
- Cancer and blood disorders: Leukemias, lymphomas, myelodysplastic syndromes, and solid tumors where the CBC tracks bone marrow function or screens for metastatic involvement. Surveillance after cancer treatment frequently qualifies as well.
- Medication monitoring: Drugs that can suppress bone marrow function or alter blood counts, including chemotherapy agents, anticonvulsants, certain antibiotics, immunosuppressants, methotrexate, and antiretrovirals. If a medication’s prescribing information calls for periodic blood count monitoring, that requirement generally satisfies medical necessity.
- Chronic diseases: Chronic kidney disease, liver disease, autoimmune conditions like rheumatoid arthritis or lupus, and chronic heart failure often warrant periodic CBCs because they affect blood cell production or cause anemia as a complication.
- Preoperative evaluation: When you are scheduled for a surgical procedure and the surgeon or anesthesiologist orders baseline blood work, a CBC is covered under the preoperative diagnosis.
- Signs and symptoms: Fatigue, pallor, dizziness, unexplained bruising, petechiae, fever of unknown origin, lymphadenopathy, and unintentional weight loss are all symptom-based codes that support a CBC order.
This is not exhaustive. Providers regularly order CBCs for pregnancy monitoring, nutritional deficiencies, coagulation workups, and post-transplant care, among many other situations. The common thread is that the provider can point to a clinical question the CBC is expected to help answer.
How National and Local Coverage Rules Work Together
Medicare’s coverage decisions come in two layers. At the top, the Centers for Medicare and Medicaid Services issues National Coverage Determinations that apply everywhere in the country. Below that, regional Medicare Administrative Contractors issue Local Coverage Determinations that can be more specific or more permissive for their jurisdiction. For laboratory tests like a CBC, the local rules often matter more in practice, because the MACs publish detailed lists of acceptable ICD-10 codes for common lab panels.
This layered system means the exact list of qualifying diagnosis codes can vary depending on where you live. A diagnosis code accepted by the MAC covering the southeastern United States might not appear on the list used by the contractor covering the Pacific Northwest, even though the underlying Medicare statute is the same.1Labcorp. Medicare Medical Necessity The differences tend to be at the margins rather than the core. Anemia, infection, and cancer surveillance qualify everywhere. The variation shows up in less common diagnoses or in how broadly a MAC interprets symptom codes.
If your provider’s office is near a state border, the MAC that processes the claim is typically determined by the location of the laboratory performing the test, not the location of the ordering physician or your home address. That can occasionally produce surprises when a lab in one state processes your blood work under a different MAC’s rules than your doctor expected.
What Happens When No Qualifying Diagnosis Exists
If your provider wants to order a CBC but does not have a covered diagnosis to attach to it, Medicare requires the laboratory to offer you an Advance Beneficiary Notice of Non-coverage before drawing your blood. The ABN is a form that explains Medicare may not pay for the test and gives you three choices: proceed and accept financial responsibility if the claim is denied, proceed and have the lab bill Medicare anyway so you can appeal a denial, or decline the test altogether.
The ABN process exists precisely because many providers order CBCs out of habit during annual visits. Research has found that roughly one in five healthy Medicare beneficiaries receive routine low-value tests during their Annual Wellness Visits, including tests that are not justified by the patient’s clinical picture.3JAMA Network Open. Assessment of Prevalence and Cost of Care Cascades After Routine Testing During the Medicare Annual Wellness Visit When those tests produce a mildly abnormal result, they can trigger follow-up tests and specialist referrals that add cost without clear benefit. For a CBC, a slightly low hemoglobin or marginally elevated white count in a healthy person can lead to iron studies, reticulocyte counts, or even a hematology referral that would not have happened without the screening test.
This does not mean a CBC during a wellness visit is automatically uncovered. If your provider notes a symptom or condition during the visit, such as fatigue you mention during the review of systems, that symptom can serve as the medical necessity justification. The critical distinction is whether the CBC is ordered to investigate something specific versus ordered as a blanket screen with no clinical indication.
The Annual Wellness Visit Misconception
A persistent source of confusion among Medicare beneficiaries is the belief that the Annual Wellness Visit includes comprehensive blood work. It does not. The AWV is a preventive planning visit that involves a health risk assessment, a review of your medical history, and screening for cognitive and functional decline. Medicare covers the visit itself at no cost to you, but it does not bundle in laboratory tests the way many people expect from a “yearly physical.”
Your provider can order a CBC at the same visit, but only if a qualifying clinical reason exists. If your chart shows a history of anemia and you are being monitored annually, the CBC is covered under the anemia diagnosis. If you are on methotrexate for rheumatoid arthritis, the medication monitoring indication covers it. If nothing in your history or current symptoms justifies the order, the CBC is considered routine screening, and Medicare will not pay.
Many beneficiaries discover this distinction only when they receive an unexpected bill. The safest approach is to ask the provider’s billing staff before the blood draw whether the CBC has a covered diagnosis code attached. If it does not, you should receive an ABN giving you the chance to decide whether to proceed at your own expense.
Cancer Surveillance and Ongoing Monitoring
One of the most common reasons Medicare beneficiaries get repeated CBCs is cancer follow-up care. After treatment for breast cancer, lung cancer, colon cancer, and many other malignancies, oncologists routinely order blood counts to watch for signs of recurrence or late effects of chemotherapy and radiation. Studies of post-treatment surveillance for breast cancer, for instance, have found that automated hemograms (the billing term that includes CBCs) account for a meaningful share of follow-up costs in the first two years after diagnosis.4Breast Cancer Research and Treatment. Clinical surveillance for early stage breast cancer: an analysis of claims data
In the oncology context, medical necessity is rarely in question. The cancer diagnosis itself, any active treatment, and the need to monitor for myelosuppression (the bone marrow-dampening effect of many chemotherapy drugs) all provide strong justification. Even years after treatment ends, a history of cancer with ongoing surveillance typically qualifies as a covered indication, though the frequency of testing may be scrutinized if it exceeds what clinical guidelines recommend.
Beneficiaries undergoing active chemotherapy or immunotherapy often get CBCs before every treatment cycle, sometimes weekly. These are almost universally covered because the drugs themselves carry known risks of dangerously low blood counts that require monitoring to keep treatment safe.
Medication Monitoring Beyond Oncology
Cancer treatment is the most dramatic example of medication-driven CBC monitoring, but plenty of common, non-oncology medications also require periodic blood counts. Methotrexate, widely prescribed for rheumatoid arthritis and psoriasis, can suppress white blood cells and platelets. Clozapine, used for treatment-resistant schizophrenia, carries a well-known risk of a dangerous drop in a specific type of white blood cell, and the prescribing program mandates regular CBC checks as a condition of continued dispensing. Certain antibiotics, antiepileptic drugs, and disease-modifying therapies for multiple sclerosis also list blood count monitoring in their labeling.
When a medication’s FDA-approved labeling or prescribing protocol calls for CBC monitoring, that requirement functions as built-in medical necessity documentation. The diagnosis code attached to the claim is typically the condition being treated (rheumatoid arthritis, schizophrenia, epilepsy) or a code specifically indicating “long-term drug therapy requiring monitoring.” Either approach generally satisfies Medicare’s requirements, though the specific code your provider uses can vary by MAC region.
When a CBC with Differential Is Ordered Instead
You may see two related tests on your lab orders: a CBC and a CBC with differential. The basic CBC gives counts of red blood cells, white blood cells, and platelets, along with measurements like hemoglobin and hematocrit. The differential adds a breakdown of the different types of white blood cells, such as neutrophils, lymphocytes, monocytes, eosinophils, and basophils. The differential is especially useful for diagnosing infections, allergies, and blood cancers because the pattern of which white cell types are elevated or depressed narrows the possibilities.2Journal of PeriAnesthesia Nursing. Understanding the complete blood count with differential
From a Medicare coverage standpoint, the same medical necessity principles apply to both versions of the test. The CBC with differential is slightly more expensive, so some MACs scrutinize it a bit more closely when the diagnosis code suggests a condition where only the basic panel would be relevant. In practice, most providers order the version with the differential by default because the added cost is small and the clinical information is more complete. If your provider has a qualifying diagnosis for a CBC, that same diagnosis almost always covers the differential version as well.
How to Avoid Surprise Bills
Understanding the coverage rules is useful, but the practical question most beneficiaries care about is how to keep unexpected charges from showing up. A few steps reduce the risk considerably.
First, if blood work is ordered during any visit, ask the provider whether each test has an associated diagnosis code that Medicare accepts. The front desk or billing coordinator can usually answer this in real time. Second, if you are handed an ABN to sign, read it carefully. The form is not a formality. It means someone in the billing chain believes Medicare may not cover the test. You have the right to decline. Third, if you have a chronic condition like anemia, diabetes, or kidney disease that has historically justified your blood work, make sure your provider is coding the CBC to that condition. Coding errors, not coverage gaps, are behind many denied claims.
If a claim is denied and you believe the test was medically necessary, you can appeal. Medicare’s appeals process starts with a redetermination by the MAC and can escalate through several levels. Denied lab claims are among the most commonly overturned on appeal, particularly when the provider submits additional documentation showing the clinical rationale.
Screening Programs That Do Include Blood Work
While Medicare does not cover a CBC as a standalone screening test, a few preventive screening programs involve blood work that may include a CBC as part of a larger panel. Initial Preventive Physical Examinations (the “Welcome to Medicare” visit available in the first 12 months of Part B enrollment) can include a referral for certain screening tests. Some cardiovascular screening benefits and diabetes screening benefits involve blood draws, though these focus on lipid panels and glucose rather than CBCs.
The distinction matters because beneficiaries sometimes conflate the preventive benefits Medicare does cover with comprehensive blood panels. Medicare covers screening colonoscopies, mammograms, and certain blood-based cancer screenings under specific preventive benefit categories, each with its own eligibility criteria. A CBC is not part of any of those screening programs. It remains a diagnostic test that requires its own clinical justification every time it is ordered.
Supplemental Medigap or Medicare Advantage plans occasionally offer broader lab coverage as an extra benefit, including wellness blood panels that go beyond what Original Medicare covers. If you have a Medicare Advantage plan, your plan’s specific formulary of covered services may include routine CBCs under certain circumstances that Original Medicare would not pay for. Checking with your plan directly is the only reliable way to know whether those extra benefits apply to you.